$4.00
7.51% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US74365U1079
Symbol
TARA
Sector
Industry

Protara Therapeutics Inc Stock price

$4.33
+0.89 25.73% 1M
+2.57 145.74% 6M
-0.96 18.09% YTD
+0.23 5.49% 1Y
-1.01 18.86% 3Y
-18.72 81.23% 5Y
-466.88 99.08% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
+0.04 0.82%
ISIN
US74365U1079
Symbol
TARA
Sector
Industry

Key metrics

Market capitalization $159.02m
Enterprise Value $-6.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.19
P/B ratio (TTM) P/B ratio 0.91
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-49.15m
Free Cash Flow (TTM) Free Cash Flow $-35.87m
Cash position $170.29m
EPS (TTM) EPS $-2.41
P/E forward negative
Short interest 5.62%
Show more

Is Protara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Protara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Protara Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Protara Therapeutics Inc forecast:

Buy
100%

Financial data from Protara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.33 0.33
54% 54%
-
-0.33 -0.33
54% 54%
-
- Selling and Administrative Expenses 17 17
2% 2%
-
- Research and Development Expense 31 31
27% 27%
-
-49 -49
14% 14%
-
- Depreciation and Amortization 0.33 0.33
54% 54%
-
EBIT (Operating Income) EBIT -49 -49
13% 13%
-
Net Profit -45 -45
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protara Therapeutics Inc Stock News

Positive
Seeking Alpha
7 days ago
TARA's leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA's pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no ot...
Neutral
GlobeNewsWire
16 days ago
Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice Conference Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-sta...
Neutral
GlobeNewsWire
about one month ago
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA...
More Protara Therapeutics Inc News

Company Profile

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Head office United States
CEO Jesse Shefferman
Employees 33
Founded 2006
Website www.protaratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today